Epiomic Epidemiology Series: Thyroid Cancer Forecast in 17 Major Markets 2015-2025

Date: December 1, 2015
Pages: 66
Price:
US$ 6,382.00
Publisher: Black Swan Analysis limited
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Hard Copy Mail Delivery
ID: ED32D6B2D89EN
Leaflet:

Download PDF Leaflet

Epiomic Epidemiology Series: Thyroid Cancer Forecast in 17 Major Markets 2015-2025
Thyroid Cancer is a cancer originating from follicular or parafollicular thyroid cells. It is a relatively rare cancer, but the most common of the endocrine system. The main clinical split is between differentiated and undifferentiated tumour types, with the majority being well-differentiated.

This report provides the current incidence population for Thyroid Cancer across 17 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, Canada, Australia, India, Mexico, Turkey, South Africa, Saudi Arabia, Argentina and Russia) split by gender and 5-year age cohort. Along with the current incidence, the report provides an overview of the stages, locations and histopathology of Thyroid Cancer tumours. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms of Thyroid Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Thyroid Cancer include:
  • Familial Adenomatous Polyposis
  • Acromegaly
  • Diabetes
  • Multiple endocrine neoplasia syndromes
  • Sipple syndrome
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global Thyroid Cancer’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of Thyroid Cancer and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Thyroid Cancer’s incident population.
  • Examination of the incidence of the different causative gene mutations for Thyroid Cancer.
  • Identify sub-populations within Thyroid Cancer which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Thyroid Cancer patients.
Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Co-morbid Conditions/ Features Associated with the Disease
Methodology for Quantification of Patient Numbers
  Additional data available on request
Top-Line Thyroid Cancer Incidence
Types of Thyroid Cancer
   Papillary Thyroid Cancer Gene Mutations
Thyroid Cancer by Stage
  Staging of Thyroid Cancer by Histological Type
Abbreviations used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

LIST OF TABLES

1. AJCC TUMOUR CLASSIFICATION FOR PTC AND FTC IN OVER 45 YEAR OLD PATIENTS
2. AJCC TUMOUR CLASSIFICATION FOR PTC AND FTC IN UNDER 45 YEAR OLD PATIENTS
3. AJCC TUMOUR CLASSIFICATION FOR MTC
4. AJCC TUMOUR CLASSIFICATION FOR ATC
5. INCIDENCE OF THYROID CANCER, TOTAL (000S)
6. INCIDENCE OF THYROID CANCER, MALES (000S)
7. INCIDENCE OF THYROID CANCER, FEMALES (000S)
8. HISTOPATHOLOGICAL TYPE IN THYROID CANCER PATIENTS, TOTAL (000S)
9. SOLITARY VERSUS MULTIFOCAL TYPE IN THYROID CANCER PATIENTS, TOTAL (000S)
10. BRAF MUTATIONS IN PTC PATIENTS, TOTAL (000S)
11. RET/PTC3 GENE REARRANGEMENT IN PTC PATIENTS, TOTAL (000S)
12. STAGE AT DIAGNOSIS FOR THYROID CANCER PATIENTS, TOTAL (000S)
13. AJCC STAGING IN PTC PATIENTS, TOTAL (000S)
14. AJCC STAGING IN FTC PATIENTS, TOTAL (000S)
15. AJCC STAGING IN MTC PATIENTS, TOTAL (000S)
16. ABBREVIATIONS AND ACRONYMS USED IN THE REPORT
17. USA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
18. USA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
19. FRANCE INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
20. FRANCE INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
21. GERMANY INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
22. GERMANY INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
23. ITALY INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
24. ITALY INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
25. SPAIN INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
26. SPAIN INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
27. UNITED KINGDOM INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
28. UNITED KINGDOM INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
29. BRAZIL INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
30. BRAZIL INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
31. JAPAN INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
32. JAPAN INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
33. INDIA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
34. INDIA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
35. AUSTRALIA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
36. AUSTRALIA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
37. CANADA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
38. CANADA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
39. MEXICO INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
40. MEXICO INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
41. TURKEY INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
42. TURKEY INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
43. SOUTH AFRICA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
44. SOUTH AFRICA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
45. SAUDI ARABIA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
46. SAUDI ARABIA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
47. ARGENTINA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
48. ARGENTINA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
49. RUSSIA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, MALES (000S)
50. RUSSIA INCIDENCE OF THYROID CANCER BY 5-YR AGE COHORT, FEMALES (000S)
Skip to top


Ask Your Question

Epiomic Epidemiology Series: Thyroid Cancer Forecast in 17 Major Markets 2015-2025
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: